HRP20160047T1 - Derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova - Google Patents
Derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova Download PDFInfo
- Publication number
- HRP20160047T1 HRP20160047T1 HRP20160047TT HRP20160047T HRP20160047T1 HR P20160047 T1 HRP20160047 T1 HR P20160047T1 HR P20160047T T HRP20160047T T HR P20160047TT HR P20160047 T HRP20160047 T HR P20160047T HR P20160047 T1 HRP20160047 T1 HR P20160047T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- oxazole
- carbonyl
- amino
- propionic acid
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 3
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 title 1
- -1 OF3 Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Chemical group 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- QYPIUHDDVALEIA-HYDPEUQHSA-N (3S)-3-[(5-methyl-2-phenyl-1,3-oxazole-4-carbonyl)amino]-3-[2-(trifluoromethyl)phenyl]propanoic acid (3S)-3-(2-methylphenyl)-3-[[2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carbonyl]amino]propanoic acid Chemical compound Cc1oc(nc1C(=O)N[C@@H](CC(O)=O)c1ccccc1C(F)(F)F)-c1ccccc1.Cc1ccccc1[C@H](CC(O)=O)NC(=O)c1nc(oc1C(F)(F)F)-c1ccccc1 QYPIUHDDVALEIA-HYDPEUQHSA-N 0.000 claims 1
- DOTDYHQEUYSROH-ZDUSSCGKSA-N (3s)-3-(2,3-dichlorophenyl)-3-[[2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carbonyl]amino]propanoic acid Chemical compound N([C@@H](CC(=O)O)C=1C(=C(Cl)C=CC=1)Cl)C(=O)C(=C(O1)C(F)(F)F)N=C1C1=CC=CC=C1 DOTDYHQEUYSROH-ZDUSSCGKSA-N 0.000 claims 1
- NVEKWAWBKFBYRY-AWEZNQCLSA-N (3s)-3-(2,4-dichlorophenyl)-3-[[2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carbonyl]amino]propanoic acid Chemical compound N([C@@H](CC(=O)O)C=1C(=CC(Cl)=CC=1)Cl)C(=O)C(=C(O1)C(F)(F)F)N=C1C1=CC=CC=C1 NVEKWAWBKFBYRY-AWEZNQCLSA-N 0.000 claims 1
- AZZLXOCLOSYMQK-AWEZNQCLSA-N (3s)-3-(3-fluorophenyl)-3-[[2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carbonyl]amino]propanoic acid Chemical compound N([C@@H](CC(=O)O)C=1C=C(F)C=CC=1)C(=O)C(=C(O1)C(F)(F)F)N=C1C1=CC=CC=C1 AZZLXOCLOSYMQK-AWEZNQCLSA-N 0.000 claims 1
- ZFEKUCJCTFACDZ-INIZCTEOSA-N (3s)-3-[[2-(2-fluorophenyl)-5-methyl-1,3-oxazole-4-carbonyl]amino]-3-[3-(trifluoromethyl)phenyl]propanoic acid Chemical compound C1([C@H](CC(O)=O)NC(=O)C=2N=C(OC=2C)C=2C(=CC=CC=2)F)=CC=CC(C(F)(F)F)=C1 ZFEKUCJCTFACDZ-INIZCTEOSA-N 0.000 claims 1
- RMWVGQZYNXCKDE-INIZCTEOSA-N (3s)-3-[[2-(2-fluorophenyl)-5-methyl-1,3-oxazole-4-carbonyl]amino]-3-[4-(trifluoromethyl)phenyl]propanoic acid Chemical compound C1([C@H](CC(O)=O)NC(=O)C=2N=C(OC=2C)C=2C(=CC=CC=2)F)=CC=C(C(F)(F)F)C=C1 RMWVGQZYNXCKDE-INIZCTEOSA-N 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- WGQNTRUWZJCBIA-UHFFFAOYSA-N 3-cyclohexyl-3-[(5-methyl-2-phenyl-1,3-oxazole-4-carbonyl)amino]propanoic acid;3-[(5-methyl-2-phenyl-1,3-oxazole-4-carbonyl)amino]-4-phenylbutanoic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1C(=O)NC(CC(O)=O)C1CCCCC1.CC=1OC(C=2C=CC=CC=2)=NC=1C(=O)NC(CC(O)=O)CC1=CC=CC=C1 WGQNTRUWZJCBIA-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- MJKXLRAJSNOJDF-USPCTWCJSA-N COC=1C=C(C=CC1)[C@H](CC(=O)O)NC(=O)C=1N=C(OC1C)C1=CC=CC=C1.COC1=CC=C(C=C1)[C@H](CC(=O)O)NC(=O)C=1N=C(OC1C)C1=CC=CC=C1 Chemical compound COC=1C=C(C=CC1)[C@H](CC(=O)O)NC(=O)C=1N=C(OC1C)C1=CC=CC=C1.COC1=CC=C(C=C1)[C@H](CC(=O)O)NC(=O)C=1N=C(OC1C)C1=CC=CC=C1 MJKXLRAJSNOJDF-USPCTWCJSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Claims (10)
1. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njihova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih,
[image]
naznačen time da je Ht odabran iz niza koji čine
[image]
G je R71-O-C(O)-;
R1 je odabran iz niza koji čine vodik, halogen, (C1-C6)-alkil, CF3, (C3-C7)-cikloalkil-CsH2s-, Ar-CsH2s-, Ar-O, (C1-Cs)-alkil-O-, (C1-C6)-alkil-S(O)m- i NC-; pri čemu s je cijeli broj odabran iz niza koji čine 0, 1, 2 i 3;
R2 je odabran iz niza koji čine vodik, halogen, (C1-C6)-alkil, OF3, (C1-C8)-alkil O-, (C1-C6)-alkil-S(O)m- i NC-;
R10 je odabran iz niza koji čine R11
R11 je Ar;
R30 je odabran iz niza koji čine (C3-C7)-cikloalkil, i R32-CuH2u-, pri čemu u je cijeli broj odabran iz niza koji čine 0, 1, 2 i 3;
R32 je odabran iz niza koji čine fenil i aromatski 5-člani ili 6-člani monociklički heterocikal koji sadrži jedan, dva ili tri identična ili različita heteroatoma u prstenu odabrana iz niza koji čine dušik, kisik i sumpor i vezan je preko ugljikovog atoma u prstenu, pri čemu fenil i heterocikal su svi proizvoljno supstituirani s jednim ili više identičnih ili različitih supstituenata odabranih iz niza koji čine halogen, (C1-C6)-alkil, (C3-C7)-cikloalkil, HO-, (C1-C6)-alkil-O-, -O-CH2-O-, -O-CF2-O-, (C1-C6)-alkil-S(O)m-, H2N-S(O)2-, (C1-C4)-alkil-NH-S(O)2-, di((C1-C4)-alkil)N-S(O)2-, H2N-, (C1-C6)-alkil-NH-, di((C1-C6)-alkil)N-, (C1-C4)-alkil-C(O)-NH-, (C1-C4)-alkil-S(O)2-NH- i NC-;
R40 je odabran iz niza koji čine vodik i (C1-C4)-alkil;
R50 je odabran iz niza koji čine vodik, (C1-C6)-alkil, HO- i (C1-C6)-alkil-O-;
R60 je odabran iz niza koji čine vodik i (C1-C6)-alkil;
R71 je vodik;
Ar, međusobno neovisno skupina Ar, je odabrana iz niza koji čine fenil i aromatski 5-člani ili 6-člani monociklički heterocikal koji sadrži jedan, dva ili tri identična ili različita heteroatoma u prstenu odabrana iz niza koji čine dušik, kisik i sumpor i vezan je preko ugljikovog atoma u prstenu, pri čemu fenil i heterocikal su svi proizvoljno supstituirani s jednim ili više identičnih ili različitih supstituenata odabranih iz niza koji čine halogen, (C1-C6)-alkil, (C1-C6)-alkil-O-, -O-CH2-O-, O-CH2-CH2-O-, -O-CF2-O-, (C1-C6)-alkil-S(O)m-, H2N-S(O)2-, CF3 i NC-;
m, međusobno neovisno broj m, je cijeli broj odabran iz niza koji čine 0, 1 i 2;
pri čemu sve cikloalkilne skupine, međusobno neovisno, su proizvoljno supstituirani s jednim ili više istovjetnih ili različitih supstituenata odabranih iz niza koji čine fluor i (C1-C4)-alkil;
pri čemu sve alkil, CsH2s, CuH2u, (CH2)x i (CH2)y skupine, međusobno neovisno, te neovisno od bilo kojih drugih supstituenata, su proizvoljno supstituirane s jednim ili više supstituenata koji su fluor.
2. Spoj s formulom I-2, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njihova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema zahtjevu 1, naznačen time da
[image]
R2 je odabran iz niza koji čine vodik, halogen, (C1-C6)-alkil, CF3, (C1-C6)-alkil-O- i NC-.
3. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njihova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema bilo kojem ili više zahtjeva od 1 i 2, naznačen time da
R30 je R32-CuH2u-, pri čemu u je cijeli broj odabran iz niza koji čine 0 i 1;
R32 je odabran iz niza koji čine fenil i aromatski 5-člani ili 6-člani monociklički heterocikal koji sadrži jedan, dva ili tri identična ili različita heteroatoma u prstenu odabrana iz niza koji čine dušik, kisik i sumpor i vezan je preko ugljikovog atoma u prstenu, pri čemu su fenil i heterocikal svi proizvoljno supstituirani s jednim ili više identičnih ili različitih supstituenata odabranih iz niza koji čine halogen, (C1-C6)-alkil, (C3-C7)-cikloalkil, HO-, (C1-C6)-alkil-O-, -O-CH2-O-, -O-OF2-O-, (C1-C6)-alkil-S(O)m-, H2N-S(O)2-, (C1-C4)-alkil-NH-S(O)2-, di((C1-C4)-alkil)N-S(O)2-, H2N-, (C1-C6)-alkil-NH-, di((C1-C6)-alkil)N-, (C1-C4)-alkil-C(O)-NH-, (C1-C4)-alkil-S(O)2-NH- i NC-;
R40 je vodik.
4. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njihova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema bilo kojem ili više zahtjeva od 1 do 3, naznačen time da
R50 je vodik;
R60 je vodik.
5. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njihova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema bilo kojem ili više zahtjeva od 1 do 4, naznačen time da
R30 je R32-CuH2u- pri čemu u je cijeli broj 0;
R40 je vodik.
6. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njihova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema bilo kojem ili više zahtjeva od 1 do 5, naznačen time da je spoj odabran iz skupa koji čine
3-cikloheksil-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-4-fenil-maslačna kiselina
(S)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-3-o-tolil-propionska kiselina
(S)-3-(2-fluoro-fenil)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(3-fluoro-fenil)-3[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(4-fluoro-fenil)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-3-fenil-propionska kiselina
(S)-3-[(5-izopropil-2-fenil-oksazol-4-karbonil)-amino]-3-fenil-propionska kiselina
(S)-3-(4metoksi-fenil)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(3-metoksi-fenil)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-3-o-tolil-propionska kiselina
(S)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-3-m-tolil-propionska kiselina
(S)-3-(3-kloro-fenil)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(R)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-4-fenil-maslačna kiselina
(S)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-3-fenil-maslačna kiselina
(S)-3-(2-kloro-fenil)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(3-cikloheksil-3-[(5-izopropil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2-fluoro-fenil)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-propionska kiselina
(S)-3-(3-fluoro-fenil)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-propionska kiselina
(S)-3-(4-fluoro-fenil)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-propionska kiselina
3-[(5-izopropil-2-fenil-oksazol-4-karbonil)-amino]-4-fenil-maslačna kiselina
(S)-3-(2-fluoro-fenil)-3-[(5-izopropil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(4-fluoro-fenil)-3-[(5-izopropil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(3-kloro-fenil)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-propionska kiselina
3-(2-kloro-fenil)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-propionska kiselina
(S)-3-(4-kloro-fenil)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-propionska kiselina
(S)-3-[(5-izopropil-2-fenil-oksazol-4-karbonil)-amlno]-3-(3-metoksi-fenil)-propionska kiselina
(S)-3-(2,3-dimetoksi-fenil)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2-kloro-fenil)-3-[(5-izopropil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
3-cikloheksil-3-[(2-fenil-5-trifluorometil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2,4-dikloro-fenil)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2,3-dikloro-fenil)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-[(2-fenil-5-trifluorometil-oksazol-4-karbonil)-amino]-3-o-tolil-propionska kiselina
(S)-3-[(5-metil-2-fenil-oksazol-4-karbonil)-amino]-3-(2-trifluorometil-fenil)-propionska kiselina
(S)-3-(3-fluoro-fenil)-3-[(2-fenil-5-trifluorometil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-3-(3-trifluorometil-fenil)-propionska kiselina
(S)-3-{[2-(2-fluoro-fenil)-5-metil-oksazol-4-karbonil]-amino}-3-(4-trifluorometilfenil)-propionska kiselina
(S)-3-(2,3-dikloro-fenil)-3-{[2-(2-fluorofenil)-5-metil-oksazol-4-karbonil]-amino}-propionska kiselina
(S)-3-(3-kloro-fenil)-3-[(2-fenil-5-trifluorometil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2-kloro-fenil)-3-[(2-fenil-5-trifluorometil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2,3-dikloro-fenil)-3-[(5-izopropil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2,4-dikloro-fenil)-3-[(5-izopropil-2-fenil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2,3-dimetoksi-fenil)-3-[(2-fenil-5-trifluorometil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2,3-dikloro-fenil)-3-[(2-fenil-5-trifluorometil-oksazol-4-karbonil)-amino]-propionska kiselina
(S)-3-(2,4-dikloro-fenil)-3-[(2-fenil-5-trifluorometil-oksazol-4-karbonil)-amino]-propionska kiselina.
7. Postupak za pripremanje spoja s formulom I ili neke njegove fiziološki prihvatljive soli, ili fiziološki prihvatljivog solvata bilo kojeg od njih prema bilo kojem ili više zahtjeva 1 do 6, naznačen time da sadrži reakciju spoja s formulom II sa spojem s formulom III,
[image]
pri čemu skupine Ht, G, R10, R11, R30, R40, R50 i R60 u spojevima s formulama II i III su definirane kao u spojevima s formulom I, a dodane funkcionalne skupine mogu biti prisutne u zaštićenom obliku ili u obliku prekursorske skupine, i skupina J u spoju s formulom II je HO-, (C1-C4)-alkil-O- ili halogen.
8. Spoj s formulom I prema bilo kojem ili više zahtjeva 1 do 6 ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih naznačen time da je za uporabu kao lijek.
9. Farmaceutski pripravak, naznačen time da sadrži barem jedan spoj s formulom I prema bilo kojem ili više zahtjeva od 1 do 6 ili njegovu fiziološki prihvatljivu sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih i farmaceutski prihvatljiv nosač.
10. Uporaba spoja s formulom I prema bilo kojem ili više zahtjeva 1 do 6 ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih naznačena time da je za proizvodnju lijeka za liječenje zatajenja srca, kongestivnog zatajenja srca, kardiomiopatija, infarkta miokarda, lijeve ventrikularne disfunkcije, srčane hipertrofije, bolesti srčanih zalistaka, hipertenzije, ateroskleroze, bolesti začepljenja perifernih arterija, restenoza, poremećaja propusnosti zalistaka, liječenja edema, tromboze, reumatoidnog artritisa, osteoartritisa, zatajenja bubrega, cistične fibroze, kroničnog bronhitisa, kronične opstruktivne plućne bolesti, astme, imunoloških bolesti, dijabetičkih komplikacija, fibroznih bolesti, boli, ishemijske ili reperfuzijske ozljede ili neurodegenerativnih bolesti, ili za zaštitu srca ili zaštitu bubrega ili kao diuretik (samostalni tretman ili tretman u kombinaciji s utvrđenim diureticima).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305971 | 2011-07-26 | ||
EP12738473.3A EP2736888B1 (en) | 2011-07-26 | 2012-07-25 | 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
PCT/EP2012/064628 WO2013014204A2 (en) | 2011-07-26 | 2012-07-25 | 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160047T1 true HRP20160047T1 (hr) | 2016-02-12 |
Family
ID=46579041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160047TT HRP20160047T1 (hr) | 2011-07-26 | 2016-01-15 | Derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova |
Country Status (22)
Country | Link |
---|---|
US (2) | US9353068B2 (hr) |
EP (2) | EP3037417B1 (hr) |
JP (2) | JP6021910B2 (hr) |
KR (1) | KR20140049019A (hr) |
CN (2) | CN103827097B (hr) |
AU (2) | AU2012288842A1 (hr) |
BR (1) | BR112014001518A2 (hr) |
CA (1) | CA2841905A1 (hr) |
CY (1) | CY1117397T1 (hr) |
DK (1) | DK2736888T3 (hr) |
ES (1) | ES2560381T3 (hr) |
HK (2) | HK1192559A1 (hr) |
HR (1) | HRP20160047T1 (hr) |
HU (1) | HUE028418T2 (hr) |
IL (2) | IL230126A (hr) |
MX (1) | MX337173B (hr) |
MY (1) | MY169319A (hr) |
PL (1) | PL2736888T3 (hr) |
PT (1) | PT2736888E (hr) |
RU (1) | RU2014107000A (hr) |
SI (1) | SI2736888T1 (hr) |
WO (1) | WO2013014204A2 (hr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3037417B1 (en) | 2011-07-26 | 2019-05-22 | Sanofi | 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
AU2012288843B2 (en) * | 2011-07-26 | 2016-08-04 | Sanofi | Substituted 3 - (thiazole - 4 - carbonyl) - or 3 - (thiazole - 2 - carbonyl) aminopropionic acid derivatives and their use as pharmaceuticals |
EA201791271A1 (ru) | 2012-05-31 | 2018-01-31 | Фенекс Фармасьютикалз Аг | ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
CN105073720B (zh) | 2013-03-28 | 2017-10-13 | 赛诺菲 | 联芳基‑丙酸衍生物及其作为药物的用途 |
CA2907903A1 (en) | 2013-03-28 | 2014-10-02 | Sanofi | Biaryl-propionic acid derivatives and their use as pharmaceuticals |
CN106459004B (zh) * | 2014-06-06 | 2020-09-15 | 研究三角协会 | 爱帕琳肽受体(apj)激动剂及其用途 |
AU2016366310C1 (en) | 2015-12-09 | 2021-09-09 | Research Triangle Institute | Improved apelin receptor (APJ) agonists and uses thereof |
JP7104690B2 (ja) | 2016-10-12 | 2022-07-21 | リサーチ トライアングル インスティテュート | 複素環式アペリン受容体(apj)アゴニスト及びそれらの使用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
PE32799A1 (es) * | 1996-12-25 | 1999-04-09 | Agrogene Ltd | Nuevo derivado del acido aminobutirico para la proteccion de enfermedades fungosas |
PT1027328E (pt) * | 1997-10-31 | 2006-11-30 | Aventis Pharma Ltd | Anilidas substituídas |
US6468977B1 (en) * | 1998-03-02 | 2002-10-22 | Apotex Inc. | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
TR200100631T2 (tr) * | 1998-08-20 | 2002-08-21 | Agouron Pharmaceuticals,Inc. | Peptit-olmayan GnRH maddeleri |
DE19858191A1 (de) * | 1998-12-17 | 2000-06-21 | Aventis Cropscience Gmbh | 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclyl-pyrimidine und ihre Verwendung als Repellentien |
US6462076B2 (en) | 2000-06-14 | 2002-10-08 | Hoffmann-La Roche Inc. | Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
JP2002326980A (ja) * | 2001-04-27 | 2002-11-15 | Nippon Nohyaku Co Ltd | ジアミド誘導体及び農園芸用薬剤並びにその使用方法 |
CN1315806C (zh) * | 2001-12-04 | 2007-05-16 | 霍夫曼·拉罗奇有限公司 | 取代的2-氨基-环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途 |
US20040072802A1 (en) | 2002-10-09 | 2004-04-15 | Jingwu Duan | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
AU2003292218A1 (en) | 2002-12-23 | 2004-07-14 | Sanofi-Aventis Deutschland Gmbh | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
EP1621529A4 (en) | 2003-03-17 | 2007-10-17 | Ube Industries | 3-AMINO-3-ARYLPROPIONIC ACID N-ALKYLESTER, METHOD FOR THE PRODUCTION AND METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF ENANTIOMERS THEREOF |
EP1493739A1 (fr) * | 2003-07-03 | 2005-01-05 | Warner-Lambert Company LLC | Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
EP1493740A1 (fr) * | 2003-07-03 | 2005-01-05 | Warner-Lambert Company LLC | Dérivés de 5-fluoro-thiophene, leur procédé de preparation, les compositions pharmaceutiques les contenant et leur utilisation comme inhibiteurs de métalloprotéinases |
WO2005032490A2 (en) * | 2003-10-08 | 2005-04-14 | Bristol-Myers Squibb Company | Cyclic diamines and derivatives as factor xa inhibitors |
JP2005145839A (ja) | 2003-11-12 | 2005-06-09 | Japan Science & Technology Agency | 新規なカテプシンa阻害剤 |
TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
US20110144128A1 (en) | 2005-01-10 | 2011-06-16 | Exelixis, Inc. | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands |
AU2007226673A1 (en) * | 2006-03-10 | 2007-09-20 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
WO2008124838A1 (en) * | 2007-04-10 | 2008-10-16 | University Of Maryland, Baltimore | Compounds that inhibit human dna ligases and methods of treating cancer |
JPWO2009028280A1 (ja) * | 2007-08-29 | 2010-11-25 | 三井化学アグロ株式会社 | ピラゾールカルボン酸誘導体及びその製造方法、並びに殺菌剤 |
US8133904B2 (en) * | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
JP5411927B2 (ja) * | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1アンタゴニストとしてのピラゾール化合物 |
EP2334651A2 (en) * | 2008-07-24 | 2011-06-22 | Theravance, Inc. | Dual-acting antihypertensive agents |
CN103896796B (zh) * | 2009-05-28 | 2016-04-27 | 诺华股份有限公司 | 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物 |
US7956054B2 (en) * | 2009-07-07 | 2011-06-07 | Theravance, Inc. | Dual-acting pyrazole antihypertensive agents |
EP2456762B1 (en) * | 2009-07-22 | 2013-10-16 | Theravance, Inc. | Dual-acting oxazole antihypertensive agents |
TWI532725B (zh) * | 2010-01-26 | 2016-05-11 | 賽諾菲阿凡提斯公司 | 經氧取代之3-雜芳醯基胺基-丙酸衍生物及其作為藥物之用途 |
ES2602835T3 (es) * | 2011-05-17 | 2017-02-22 | Waterdiam Sàrl | Método para tratar cítricos después de la cosecha |
US8513244B2 (en) * | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
EP3037417B1 (en) | 2011-07-26 | 2019-05-22 | Sanofi | 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
-
2012
- 2012-07-25 EP EP15190731.8A patent/EP3037417B1/en not_active Not-in-force
- 2012-07-25 EP EP12738473.3A patent/EP2736888B1/en not_active Not-in-force
- 2012-07-25 CN CN201280046863.1A patent/CN103827097B/zh not_active Expired - Fee Related
- 2012-07-25 WO PCT/EP2012/064628 patent/WO2013014204A2/en active Application Filing
- 2012-07-25 KR KR1020147004756A patent/KR20140049019A/ko not_active Application Discontinuation
- 2012-07-25 PL PL12738473T patent/PL2736888T3/pl unknown
- 2012-07-25 CN CN201511021647.3A patent/CN105646362B/zh not_active Expired - Fee Related
- 2012-07-25 SI SI201230439T patent/SI2736888T1/sl unknown
- 2012-07-25 MX MX2014000598A patent/MX337173B/es active IP Right Grant
- 2012-07-25 DK DK12738473.3T patent/DK2736888T3/da active
- 2012-07-25 MY MYPI2013004643A patent/MY169319A/en unknown
- 2012-07-25 JP JP2014522086A patent/JP6021910B2/ja not_active Expired - Fee Related
- 2012-07-25 AU AU2012288842A patent/AU2012288842A1/en not_active Abandoned
- 2012-07-25 HU HUE12738473A patent/HUE028418T2/en unknown
- 2012-07-25 ES ES12738473.3T patent/ES2560381T3/es active Active
- 2012-07-25 RU RU2014107000/04A patent/RU2014107000A/ru not_active Application Discontinuation
- 2012-07-25 BR BR112014001518A patent/BR112014001518A2/pt not_active IP Right Cessation
- 2012-07-25 PT PT127384733T patent/PT2736888E/pt unknown
- 2012-07-25 CA CA2841905A patent/CA2841905A1/en not_active Abandoned
- 2012-07-26 US US13/559,401 patent/US9353068B2/en active Active
-
2013
- 2013-12-23 IL IL230126A patent/IL230126A/en not_active IP Right Cessation
-
2014
- 2014-06-19 HK HK14105865.5A patent/HK1192559A1/xx not_active IP Right Cessation
-
2016
- 2016-01-15 HR HRP20160047TT patent/HRP20160047T1/hr unknown
- 2016-02-03 CY CY20161100093T patent/CY1117397T1/el unknown
- 2016-04-27 US US15/140,350 patent/US9751858B2/en not_active Expired - Fee Related
- 2016-09-30 JP JP2016192793A patent/JP6360534B2/ja not_active Expired - Fee Related
- 2016-12-06 HK HK16113874A patent/HK1225714A1/zh unknown
-
2017
- 2017-01-31 IL IL250370A patent/IL250370A0/en unknown
- 2017-06-02 AU AU2017203739A patent/AU2017203739A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160047T1 (hr) | Derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova | |
HRP20150075T1 (hr) | Kisikom supstituirani derivati 3-heteroarilaminopropionske kiseline i njihova upotreba kao farmaceutska sredstva | |
Rostom et al. | Design and synthesis of some thiazolyl and thiadiazolyl derivatives of antipyrine as potential non-acidic anti-inflammatory, analgesic and antimicrobial agents | |
ES2375576T3 (es) | Derivados del �?cido (4-(4-[6-(trifluorometil-piridin-3-ilamino)-heteroarilo con contenido de n]-fenil)-ciclohexil)-acético y sus usos farmacéuticos. | |
CA3038903A1 (en) | Benzo[b]thiophene compounds as sting agonists | |
HRP20171258T1 (hr) | Acilamino-supstituirani kondenzirani derivati ciklopentankarboksilne kiseline i njihova upotreba kao farmaceutski proizvodi | |
ES2452868T3 (es) | Nuevos inhibidores de desacetilasas de histonas basados simultáneamente en 1H-pirroles trisustituidos y en espaciadores aromáticos y heteroaromáticos | |
JP2013522222A5 (hr) | ||
JP2017504650A5 (hr) | ||
JP2009524678A5 (hr) | ||
JP2011509949A5 (hr) | ||
Catarro et al. | Nimesulide analogues: From anti-inflammatory to antitumor agents | |
HRP20140691T1 (hr) | Supstituirani derivati karbamoilmetilamino octene kiseline kao novi nep-inhibitori | |
BRPI0720043A2 (pt) | Composto oxadiazol | |
WO2008023783A1 (fr) | Composé amine | |
JP2013522376A5 (hr) | ||
JP2014037426A5 (hr) | ||
JP2013532652A5 (hr) | ||
WO2013066833A1 (en) | Compounds and methods to inhibit histone deacetylase (hdac) enzymes | |
Giles et al. | Synthesis pharmacological evaluation and docking studies of pyrimidine derivatives | |
ES2661394T3 (es) | Derivados de di- y tri-heteroarilo como inhibidores de la agregación de proteínas | |
ES2408654T3 (es) | Tiazopirimidinonas y uso de las mismas | |
JP2013525293A5 (hr) | ||
JP2016539985A5 (hr) | ||
JP2016508135A5 (hr) |